Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology Co., Ltd. has proposed electing current board secretary and joint company secretary Tian Min as an additional executive director, reflecting efforts to enhance corporate governance, board diversity and long-term development. Tian, a legally trained executive who has held multiple roles across the group’s subsidiaries since 2015, holds A shares in the company and brings substantial internal experience to the board.
The company also plans to replace three long-serving independent non-executive directors, who will step down in June 2026 upon reaching the six-year regulatory limit under CSRC rules. It has nominated valuation and governance expert Chan Sui Yu, along with Song Yuanyang and Xu Duoqi, as new independent directors, moves that aim to maintain compliance while refreshing oversight and strengthening expertise in areas such as asset appraisal, ESG and corporate governance for stakeholders.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a PRC‑incorporated medical and biotechnology group listed in Hong Kong, focusing on biological and medical technology products through multiple specialized subsidiaries. The company operates within China’s healthcare and biotech sector, with an emphasis on high-quality development and strengthened corporate governance as it expands its portfolio and organizational structure.
Average Trading Volume: 156,816
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.46B
For a thorough assessment of 6826 stock, go to TipRanks’ Stock Analysis page.